Effects of Supplemental Dexmedetomidine Anesthesia on Intracranial Aneurysm Patients Undergoing Intracranial Interventional Embolization

- BACKGROUND: Intracranial aneurysm (IA) has been identified in approximately 0.4%L3% of the population and associated with 3%L10% mortality. IA is the major factor attributing to spontaneous subarachnoid hemorrhage. We aim to investigate that whether employing dexmedetomidine (DEX), an a2 adrenergic receptor agonist, as a supplementation could impact the outcomes of patients with intracranial interventional embolization. - METHODS: Patients were randomly divided into a control group (n = 48 cases) and a DEX (0.6 mg/kg) supplement group (n [ 48 cases). Patients' outcomes were evaluated using the Glasgow Outcome Scale. Serum levels of norepinephrine, cortisol, interleukin-6, Creactive protein, neuron-specific enolase, and S100 beta were determined using enzyme-linked immunoassay. The cognitive function of patients was assessed using the Mini-Mental State Exam and Montreal Cognitive Assessment tests. - RESULTS: DEX supplementation during anesthesia reduced adverse reaction, surgical stress, and attenuated cognitive impairment after extubation in IA patients' postintracranial interventional embolization. - CONCLUSIONS: Our study demonstrated that employing DEX as supplementation during anesthesia could effectively reduce surgical stress and improve cognitive function, ultimately improving patients' recovery from intracranial interventional embolization.